Medicate International Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-11-2024
- Paid Up Capital ₹ 1.00 M
as on 17-11-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 Cr
as on 17-11-2024
- Revenue -13.60%
(FY 2023)
- Profit -23.24%
(FY 2023)
- Ebitda -4.02%
(FY 2023)
- Net Worth 102.24%
(FY 2023)
- Total Assets 22.19%
(FY 2023)
About Medicate International
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.00 Cr.
Ashwini Tripathi and Laxmi serve as directors at the Company.
- CIN/LLPIN
U74140DL2015PTC280215
- Company No.
280215
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Medicate International Private Limited offer?
Medicate International Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Injection, Antibiotic Tablets & Capsules, Cycloserine Capsule, Anti Cancer Medicines, Xbira Tablet, Melphalan Tablets, Alphalan Melphalan, Geftinat Tablet, Anti Infective Drugs & Medicines.
Who are the key members and board of directors at Medicate International?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashwini Tripathi  | Director | 14-May-2015 | Current |
| Laxmi | Director | 14-May-2015 | Current |
Financial Performance of Medicate International.
Medicate International Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.6% decrease. The company also saw a substantial fall in profitability, with a 23.24% decrease in profit. The company's net worth Soared by an impressive increase of 102.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medicate International?
In 2022, Medicate International had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- W&B Health Care Private LimitedActive 11 years 3 months
Ashwini Tripathi and Laxmi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Jun 2017 | ₹1.00 Cr | Open |
How Many Employees Work at Medicate International?
Unlock and access historical data on people associated with Medicate International, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medicate International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medicate International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
